Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Instituto Nacional de Cancer, Brazil
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05800834CT.gov Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds | — | Unknown | — | — | — |
NCT05072314CT.gov Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial | — | Recruiting | — | — | — |
NCT04874038CT.gov Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN) | — | Recruiting | — | — | — |
NCT04822597CT.gov Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer | — | Completed | — | — | — |
NCT04336917CT.gov Ultrasound Guided Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Surgeries | — | Completed | — | — | — |
NCT04438577CT.gov Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery | — | Unknown | — | — | — |
NCT04275661CT.gov Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery | — | Completed | — | — | — |
NCT02822196CT.gov Serratus Anterior Muscle Plane Block vsThoracic Paravertebral Block For Unilateral Mastectomies | — | Withdrawn | — | — | — |
NCT02839668CT.gov The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC) | — | Completed | — | — | — |
NCT02647385CT.gov Pain Control in Breast Surgery: Analgesia, Opioid Consumption and Inflammatory Response Evaluation | — | Active Not Recruiting | — | — | — |
Show 4 more trialsShow fewer
NCT02185859CT.gov Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Breast Mastectomy | — | Completed | — | — | — |
NCT03456661CT.gov Comparison Between Levobupivacaine and Levobupivacaine With Dexmedetomidine in Ultrasound Guided Pectoral Nerve Block | — | Terminated | — | — | — |
NCT02625506CT.gov Efficacy of Tramadol With Levobupivacaine for Modified Pectoral Nerve Block | — | Completed | — | — | — |
NCT01539317CT.gov Therapy to Prevent Sexual Pain in Breast Cancer Survivors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lidocaine (this asset) | Instituto Nacional de Cancer, Brazil | Approved | BB · 67 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Lidocaine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral Neuropathy | — | P4 | BBB · 79 |
| Postherpetic Neuralgia | — | P4 | BBB · 78 |
| Post-Operative Pain, Non-Human Animal | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lidocaine in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lidocaine-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →